アミロイド症治療法の世界市場予測・分析2019-2023

◆英語タイトル:Amyloidosis Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32054
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月28日
◆ページ数:154
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、アミロイド症治療法の世界市場について調べ、アミロイド症治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、アミロイド症治療法の市場規模をセグメンテーション別(種類別(全身性アミロイドーシス、その他のアミロイドーシス)、)と地域別(グローバル)に分けて算出しました。Technavio社はアミロイド症治療法の世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・アミロイド症治療法の市場状況
・アミロイド症治療法の市場規模
・アミロイド症治療法の市場予測
・アミロイド症治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(全身性アミロイドーシス、その他のアミロイドーシス)
・アミロイド症治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Amyloidosis Therapeutics Market: About this market

Technavio’s amyloidosis therapeutics market analysis considers sales from systemic amyloidosis and other amyloidosis types. Our analysis also considers the sales of amyloidosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the systemic amyloidosis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of the condition and recent drug approvals will play a significant role in the systemic amyloidosis segment to maintain its market position. Also, our global amyloidosis therapeutics market report looks at factors such as high prevalence of associated risk factors of amyloidosis, growth of geriatric population, and increasing research funding for rare diseases. However, lack of curative therapies, difficulty in diagnosis, and high cost of approved therapies may hamper the growth of the amyloidosis therapeutics industry over the forecast period.

Global Amyloidosis Therapeutics Market: Overview

Increasing research funding for rare disease

The global amyloidosis therapeutics market has only three approved drugs for the treatment of the condition. Although the amyloidosis is rare, the increasing prevalence of the condition and the lack of approved therapies have resulted in an unmet need for treatment using drugs that are available in the market. This has resulted in the intense R&D of novel therapies by vendors and research institutes for the development of treatment options for amyloidosis. Many organizations, such as Vasculitis Foundation and National Organization for Rare Disorders, have been providing research funding to small or mid-sized companies to complete their clinical trials and launch drugs. This Increasing research funding will lead to the expansion of the global amyloidosis therapeutics market at a CAGR of almost 8% during the forecast period.

Special drug designations

Drugs that treat amyloidosis and therapeutic candidates (under development) for the treatment of the condition have been awarded special drug designations by regulatory bodies considering their proven efficacy. Many such drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The sponsors of these drugs receive various incentives and tax benefits, encouraging vendors to expedite R&D on new molecules. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global amyloidosis therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global amyloidosis therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading amyloidosis therapeutics manufacturers, that include AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the amyloidosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Systemic amyloidosis – Market size and forecast 2018-2023

Other amyloidosis – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing awareness about rare diseases

Special drug designations

Strategic alliances

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AbbVie Inc.

Allergan Plc

Alnylam Pharmaceuticals Inc.

Amgen Inc.

Celgene Corp.

GlaxoSmithKline Plc

Ionis Pharmaceuticals Inc.

Johnson & Johnson Services Inc.

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Systemic amyloidosis – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Systemic amyloidosis – Year-over-year growth 2019-2023 (%)

Exhibit 22: Other amyloidosis – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Other amyloidosis – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by type

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Proportion of geriatric population in Asia 2009 and 2018

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Prevalence/incidence of associated risk factors of amyloidosis

Exhibit 44: Growth of geriatric population 2014-2018 (%)

Exhibit 45: Cost of approved drugs for treatment of amyloidosis in the US

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Drug designations

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendors covered

Exhibit 51: Vendor classification

Exhibit 52: Market positioning of vendors

Exhibit 53: AbbVie Inc. – Vendor overview

Exhibit 54: AbbVie Inc. – Business segments

Exhibit 55: AbbVie Inc. – Organizational developments

Exhibit 56: AbbVie Inc. – Geographic focus

Exhibit 57: AbbVie Inc. – Key offerings

Exhibit 58: AbbVie Inc. – Key customers

Exhibit 59: Allergan Plc – Vendor overview

Exhibit 60: Allergan Plc – Business segments

Exhibit 61: Allergan Plc – Organizational developments

Exhibit 62: Allergan Plc – Geographic focus

Exhibit 63: Allergan Plc – Segment focus

Exhibit 64: Allergan Plc – Key offerings

Exhibit 65: Allergan Plc – Key customers

Exhibit 66: Alnylam Pharmaceuticals Inc. – Vendor overview

Exhibit 67: Alnylam Pharmaceuticals Inc. – Business segments

Exhibit 68: Alnylam Pharmaceuticals Inc. – Organizational developments

Exhibit 69: Alnylam Pharmaceuticals Inc. – Key offerings

Exhibit 70: Alnylam Pharmaceuticals Inc. – Key customers

Exhibit 71: Amgen Inc. – Vendor overview

Exhibit 72: Amgen Inc. – Business segments

Exhibit 73: Amgen Inc. – Organizational developments

Exhibit 74: Amgen Inc. – Geographic focus

Exhibit 75: Amgen Inc. – Key offerings

Exhibit 76: Amgen Inc. – Key customers

Exhibit 77: Celgene Corp. – Vendor overview

Exhibit 78: Celgene Corp. – Business segments

Exhibit 79: Celgene Corp. – Organizational developments

Exhibit 80: Celgene Corp. – Geographic focus

Exhibit 81: Celgene Corp. – Key offerings

Exhibit 82: Celgene Corp. – Key customers

Exhibit 83: GlaxoSmithKline Plc – Vendor overview

Exhibit 84: GlaxoSmithKline Plc – Business segments

Exhibit 85: GlaxoSmithKline Plc – Organizational developments

Exhibit 86: GlaxoSmithKline Plc – Geographic focus

Exhibit 87: GlaxoSmithKline Plc – Segment focus

Exhibit 88: GlaxoSmithKline Plc – Key offerings

Exhibit 89: GlaxoSmithKline Plc – Key customers

Exhibit 90: Ionis Pharmaceuticals Inc. – Vendor overview

Exhibit 91: Ionis Pharmaceuticals Inc. – Business segments

Exhibit 92: Ionis Pharmaceuticals Inc. – Organizational developments

Exhibit 93: Ionis Pharmaceuticals Inc. – Key offerings

Exhibit 94: Ionis Pharmaceuticals Inc. – Key customers

Exhibit 95: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 96: Johnson & Johnson Services Inc. – Business segments

Exhibit 97: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 98: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 99: Johnson & Johnson Services Inc. – Segment focus

Exhibit 100: Johnson & Johnson Services Inc. – Key offerings

Exhibit 101: Johnson & Johnson Services Inc. – Key customers

Exhibit 102: Pfizer Inc. – Vendor overview

Exhibit 103: Pfizer Inc. – Business segments

Exhibit 104: Pfizer Inc. – Organizational developments

Exhibit 105: Pfizer Inc. – Geographic focus

Exhibit 106: Pfizer Inc. – Segment focus

Exhibit 107: Pfizer Inc. – Key offerings

Exhibit 108: Pfizer Inc. – Key customers

Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 111: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 112: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 113: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 114: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 115: Validation techniques employed for market sizing

Exhibit 116: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アミロイド症治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆